[ad_1]
Patients who have nowhere to rely on the transfer of responsibility
Neglect of advanced biological management due to ‘classification ambiguity’
Application of the ‘Advanced Bio Law’ … “There are still many things to compensate”
[앵커]
YTN, which reports in-depth reports on the suspicion and controversy surrounding stem cell treatment, yesterday reported the case of an elderly man in his 70s who died after unauthorized stem cell treatment. Although stem cell treatments that have not been proven safe and effective have been carried out in this way, the government is still trying to relax regulations. This is reporter Seung-Hwan Kim from the Planning and Exploration Team. Unauthorized stem cell treatment in the blind spot of the law. The hospital’s articulation that crosses the border between legal and illegal attracts desperate patients. It is the patients who end up being harmed by expensive stem cell treatments that have not been proven safe or effective. There is no place to trust harm. As the government loses its hands on handling stem cell therapy, it is only busy shifting responsibility. Responsibility for the management of stem cell treatment is divided between the Ministry of Health and Welfare and the Ministry of Food and Pharmaceutical Safety. If cells have been cultured, they are classified as therapeutic and are managed by the Ministry of Food and Drug Safety from approval review to post-marketing management. However, advanced biological fields like stem cells have been neglected because the classification system for the stability of raw materials is ambiguous. That is why the ‘Advanced Regeneration Bio Method’ was created. It means that the state will actively step in and manage high-tech medical fields such as stem cell therapy. There is also a concern that the space for opinions to be reflected is greater than before. From the Roh Moo-hyun administration to the Lee Myung-bak and Park Geun-hye administrations, successive governments have been criticized for promoting the field of stem cells from an overly industrial perspective. It is pointed out that related policies should be promoted in a direction that ultimately benefits public health by solidifying the foundation, but the government appears not to have changed much. Simplifying unnecessary processes and lowering the threshold for permits and approvals are very different. The United States and Europe, which are advanced medical countries, are striving to simplify the licensing process while still respecting the principle of “reasonable medical evidence” licensing. This is YTN Kim Seung-hwan.